The Recall Desk
Agency classClass IIOur severity:ModerateFDA (Drugs)·D-1599-2020·Announced 2020-09-23

RLC Labs Recalls Nature-Throid Tablets Due to CGMP Deviations

RLC Labs Inc. is recalling Nature-Throid tablets due to Current Good Manufacturing Practice (CGMP) deviations. The product was manufactured under conditions found to be subpotent.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

What this means for you

Our assessment, not the agency’s: severity 2/5 (Moderate).

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II. The source text does not report any illnesses, injuries, or hospitalizations, and the hazard is related to manufacturing deviations rather than a specific high-risk pathogen or structural defect.

Plain-English summary

RLC Labs Inc. is voluntarily recalling Nature-Throid, Thyroid USP tablets. The recall is due to Current Good Manufacturing Practice (CGMP) deviations. The source text states that the product was manufactured under the same conditions as those found to be subpotent.

The affected product includes Nature-Throid tablets containing liothyronine (T3) 11.25 mcg and levothyroxine (T4) 47.5 mcg. The tablets are packaged in 30-count, 60-count, 90-count, 100-count, and 1,000-count bottles. The recall covers all lots with expiry dates between October 2020 and July 2023. The product was distributed nationwide in the United States.

Consumers should stop using the recalled product and contact their healthcare provider or pharmacist for guidance. The recall is classified as Class II by the FDA.

The recalled product

Product
Nature-Throid, Thyroid USP [liothyronine (T3) 11.25 mcg and levothyroxine (T4) 47.5 mcg], 1.25 Grain (81.25 mg) Tablets, packaged in a) 30-count bottles, NDC 64727-3303-4; b) 60-count bottles, NDC 64727-3303-5; c) 90-count bottles, NDC 64727-3303-6; d) 100-count bottles, NDC…
Manufacturer
RLC Labs Inc.
Category
Drug — Thyroid Hormone
Hazard

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots with expiry between10/2020-07/2023

Distribution

Distributed nationwide across the United States.

Part of a larger recall action

This product is one of 24 recalled by RLC Labs Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 24 products in this recall →

Related recalls

Same manufacturer · RLC Labs Inc.

See all →

Same hazard · cgmp deviation

See all →

Similar recalls